• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    US Pharmaceuticals Ishares ETF (NY: IHE )

    70.81 -0.60 (-0.84%)
    Streaming Delayed Price Updated: 12:27 PM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12,109
    Open 71.58
    Bid (Size) 70.75 (2)
    Ask (Size) 70.79 (4)
    Prev. Close 71.41
    Today's Range 70.81 - 71.88
    52wk Range 55.36 - 72.94
    Shares Outstanding 95,000
    Dividend Yield 5.10%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    A Look At Pharma ETFs Post Q1 Earnings
    Pharma ETFs have delivered mixed performances over the past month. 
    Via Talk Markets
    Topics ETFs
    ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
    Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest... 
    Via Talk Markets
    Topics ETFs

    Performance

    YTD
    +13.14%
    +13.14%
    1 Month
    +5.66%
    +5.66%
    3 Month
    +6.66%
    +6.66%
    6 Month
    +4.10%
    +4.10%
    1 Year
    +13.90%
    +13.90%

    More News

    Read More
    April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    3 Sector ETFs That Beat The Market Last Week
    Via Talk Markets
    Topics ETFs
    US Pharmaceuticals: A Bifurcated Market
    Via Talk Markets
    Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
    Via Benzinga
    A Look At Pharma ETFs After Q4 Earnings
    Via Talk Markets
    Topics ETFs
    Bank Of America Predicts 10 2024 Market Surprises: From Booming IPOs To Japanese Equity Surge
    Via Benzinga
    Topics Bonds
    Exposures Debt Markets
    3 Beaten-Down ETFs To Buy For A Turnaround In 2024
    Via Talk Markets
    Topics ETFs
    Exposures COVID-19
    5 Secret Santa ETFs That Might Surprise You This Christmas
    Via Talk Markets
    Topics ETFs
    Pharmacy Workers Strike At CVS and Walgreens, Echoing Wider Pharma Sector Unrest
    Via Benzinga
    5 Sector ETFs That Outperformed in Turbulent August
    Via Talk Markets
    Topics ETFs
    Q2 Earnings & Market Sell-Off Impact: 5 Must-See ETF Charts
    Via Talk Markets
    Topics ETFs
    Pharma ETFs in Focus Post Q2 Earnings
    Via Talk Markets
    Topics ETFs
    3 Biotech Stocks to Sell in June Before They Crash and Burn
    Via InvestorPlace
    Pharma ETFs Gain Post Q1 Earnings
    Via Talk Markets
    A Look At Pharma ETFs Post Q4 Earnings
    Via Talk Markets
    4 Sector ETFs To Watch Ahead Of Mid-Election Results
    Via Talk Markets
    5 ETFs To Watch After 2022 Midterm Elections: Which Sectors Win From Republican Or Democrat Majority?
    Via Benzinga
    Pharma ETFs In Focus Post Q3 Earnings
    Via Talk Markets
    ETF Mid-Year Outlook & Investing Strategies
    Via Talk Markets
    Wave of Solid Q3 Earnings Push Pharma ETFs Higher
    Via Talk Markets
    J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
    Via Talk Markets
    Exposures COVID-19
    Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
    Via Talk Markets
    Exposures COVID-19 Product Safety
    3 Dividend-Paying Pharmaceutical Stocks to Buy This Summer
    Via Talk Markets
    Exposures COVID-19
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.